Encephalitozoon cuniculi (E. cuniculi) is a mammalian microsporidial pathogen with world-wide distribution. An important cause of neurologic and renal disease in rabbits, E. cuniculi can also cause disease in immunocompromised people.
Classification and cell structure
E. cuniculi is a spore-forming unicellular parasite belonging to the phylum Microsporidia. Microsporidia are obligate intracellular parasitic fungi infecting many animal groups. Lacking mitochondria and peroxysomes, these unicellular eukaryotes were first considered a deeply branching protist lineage that diverged before the endosymbiotic event that led to mitochondria. The discovery of a gene for a mitochondrial-type chaperone combined with molecular phylogenetic data later implied that microsporidia are atypical fungi that lost mitochondria during evolution. Its genome consists of approximately 2.9-megabases (Mbs) in 11 chromosomes, with a total of 1,997 potential protein-coding genes. Genome compaction is reflected by reduced intergenic spacers and by the shortness of most putative proteins relative to their eukaryote orthologues. The strong host dependence is illustrated by the lack of genes for some biosynthetic pathways and for the tricarboxylic acid cycle. Phylogenetic analysis lends substantial credit to the fungal affiliation of microsporidia. Because the E. cuniculi genome contains genes related to some mitochondrial functions (for example, Fe-S cluster assembly), it is possible that microsporidia have retained a mitochondrion-derived organelle.
Life cycle and pathogenesis
The infective form of microsporidia (E. cuniculi) is a resistant spore which can survive for a long time in the environment. The spore extrudes its polar tubule and infects the host cell. The spore injects the infective sporoplasm into the eukaryotic host cell through a polar tube. Inside the cell, the sporoplasm undergoes extensive multiplication. This multiplication occurs either by merogony (binary fission) or schizogony (multiple fission). Microsporidia develop by sporogony to mature spores in the cytoplasm or inside parasitophorous vacuole. During sporogony, a thick wall is formed around the spore. The thick wall formed provides resistance to adverse environmental conditions. Once the spores increase in number and completely fill the cytoplasm of the host's cell, the cell membrane is disrupted and releases the spores to the surroundings. These free mature spores can infect new cells thus continuing the cycle.
First identified in rabbits, E. cuniculi infections have been reported worldwide in over 20 mammalian species, including humans. Prevalence in pet rabbits is high, with 23-75% having antibodies to the disease. Studies of healthy dogs have found a 0-38% prevalence. Cats appear to be relatively resistant to the organism, although experimental infections in kittens with feline leukemia virus have been described. E. cuniculi also infects rodents, and the organism has been detected in the feces of 13% of pet birds. A small percentage of healthy people have antibodies to the organism, indicating previous exposure. Seroprevalence rates are higher in immunocompromised people, and in those who live in or have visited tropical countries. Most infections do not result in clinical disease.
E. cuniculi spores are usually shed in urine, but can also be found in the feces and respiratory secretions of infected animals. Spores can be detected in urine 38-63 days after infection, with intermittent shedding thereafter. Ingestion of spores is the main route of transmission, although inhalation of spores can also occur. Transplacental and intrauterine infections have been documented in rabbits.
Infections in rabbits
Up to 80% of rabbits in the United State and Europe are serologically positive for E. cuniculi, which indicates that they have been exposed to the organism. Most of these animals will remain asymptomatic and never show signs of disease. Only a small minority of infected rabbits develop the disease encephalitozoonosis. The most common clinical signs associated with this disease involve the central nervous system, eyes, and kidneys.
Most rabbits with neurologic signs show vestibular dysfunction only. Symptoms often appear suddenly, and include head tilt, ataxia, nystagmus, and circling. Most of these animals are still aware of their surroundings and are eating despite their loss of balance. More severely affected rabbits, such as those which can no longer stand, have a worse prognosis.
E. cuniculi infections in the eye cause cataract formation, white intraocular masses, and uveitis. Symptoms usually occur in young rabbits, and only one eye is generally affected. Rabbits with ocular lesions related to encephalitozoonosis are usually otherwise healthy, and tolerate vision loss well.
E. cuniculi has a predilection for the kidneys and can cause chronic or acute kidney failure. Symptoms of renal impairment include increased water consumption, increased urine output, loss of appetite, weight loss, lethargy, and dehydration. Milder cases do not cause symptoms, and signs of infection may be an incidental finding on necropsy.
It is currently difficult to definitively diagnose E. cuniculi infections in live rabbits. A presumptive diagnosis is often made based on consistent clinical signs and high antibody levels. Serology tests that look for IgG antibodies are commonly run, and can be used to rule out the disease if negative. However, a positive IgG titer cannot differentiate an active infection from a previous infection or an asymptomatic carrier state. Tests for IgM antibodies are also available, but again positive results cannot distinguish between active and latent infections.
Polymerase chain reaction (PCR) has long been established as the standard technique for detection of microsporidia in humans, and attempts to apply this to rabbits are ongoing. Studies have found that PCR of liquified lens material is a reliable means of diagnosing E. cuniculi uveitis in rabbits, but PCR testing of rabbit urine and cerebrospinal fluid is not reliable.
A few studies have shown that fenbendazole, a benzimidazole drug, can prevent and treat naturally acquired and experimentally induced E. cuniculi infections. Unfortunately the elimination of spores from the central nervous system does not always result in resolution of clinical signs. Adverse reactions to benzimidazole drugs, including injury to the small intestine and bone marrow, have been reported in rabbits. Practitioners should strictly adhere to recommended dosages and treatment intervals, and consider monitoring complete blood counts during treatment.
Infections in humans
E. cuniculi is an important opportunistic pathogen in people, particularly those immunocompromised by HIV/AIDS, organ transplantation, or CD4+ T-lymphocyte deficiency. As this organism is more common in animals than people it is likely a zoonotic disease. Three different strains of E. cuniculi have been identified, and are classified as I (rabbit), II (mouse), and III (dog). Human-to-human transmission is possible via transplantation of solid organs from an infected donor.
- Weese, J. Scott (2011). Companion animal zoonoses. Wiley-Blackwell. p. 282–284. ISBN 9780813819648.
- Oglesbee, Barbara (2011). Blackwell's Five-Minute Veterinary Consult: Small Mammal (Second ed.). West Sussex, UK: Wiley-Blackwell. p. 455. ISBN 978-0-8138-2018-7.
- Künzel, Frank; Fisher, Peter G. (January 2018). "Clinical Signs, Diagnosis, and Treatment of Encephalitozoon cuniculi Infection in Rabbits". Veterinary Clinics of North America: Exotic Animal Practice. 21 (1): 69–82. doi:10.1016/j.cvex.2017.08.002. PMID 29146032.
- Quesenberry, Katherine (2012). Ferrets, rabbits, and rodents : clinical medicine and surgery (3rd ed.). Elsevier/Saunders. p. 247–250. ISBN 978-1-4160-6621-7.
- Hocevar SN, Paddock CD, Spak CW, Rosenblatt R, Diaz-Luna H, Castillo I, Luna S, Friedman GC, Antony S, Stoddard RA, Tiller RV, Peterson T, Blau DM, Sriram RR, da Silva A, de Almeida M, Benedict T, Goldsmith CS, Zaki SR, Visvesvara GS, Kuehnert MJ, for the Microsporidia Transplant Transmission Investigation Team (2014). "Microsporidiosis acquired through solid organ transplantation: a public health investigation". Ann Intern Med. 160 (4): 213–20. doi:10.7326/M13-2226. PMC 4627638. PMID 24727839.